Professional profile
About Xu
Senior Partner | Private equity and funds, capital markets, corporate and M&A, advanced manufacturing, life sciences
Xu Min is a senior partner in Tongshang Law Offices’ Hefei office whose practice focuses on private equity and funds, securities and capital markets, and corporate and M&A. Her official profile notes an earlier engineering background at a central state-owned enterprise and identifies familiarity with new energy, new materials, intelligent manufacturing and biopharmaceutical sectors. She provides full-cycle services to funds and investment institutions across fundraising, investment, management and exit and also advises on corporate restructuring, equity incentives, governance and listing.
Read full profile
This combined engineering and investment background is particularly relevant in Hefei, where many venture-backed companies operate in technically complex industries. An investor in a semiconductor equipment, advanced-materials, quantum, medical-device or biotech company cannot rely on a purely financial diligence process. The investment thesis may depend on patents, research teams, regulatory approvals, supply-chain capabilities and a future IPO. Legal terms need to be designed around those sector realities.
Xu’s profile describes long-term service to funds and investment institutions and involvement as an investment committee or evaluation expert. That suggests familiarity with how legal findings are translated into actual investment decisions. A fund does not need a generic memorandum stating every possible risk. It needs to know which issue affects valuation, which must be fixed before closing, which can be addressed through representations or indemnities and which could prevent the expected exit.
Her capital-markets and M&A work also matters because many PE investments are structured around a future listing or sale. Investment agreements may contain redemption rights, valuation-adjustment arrangements, investor vetoes, liquidation preferences, anti-dilution provisions and founder obligations. These terms can be commercially important during the private-company phase but may need to be modified before an IPO.
A recurring issue arises when the company fails to achieve an agreed IPO milestone. Investors may seek redemption from founders, controlling shareholders or the company itself. The legal result can differ depending on who gave the obligation and how actual performance interacts with mandatory company-law rules on capital maintenance, share repurchase or capital reduction. The Supreme People’s Court’s Ninth National Courts’ Civil and Commercial Trial Work Conference Minutes provide important guidance on valuation-adjustment agreements involving target companies.
Xu’s experience with equity investments and financial disputes is relevant because redemption rights become meaningful only when they can be enforced against a solvent obligor. The investment team should therefore consider enforcement at signing, not after the IPO deadline is missed. Founder guarantees, security, payment schedules and target-company obligations should be structured carefully.
Her sector background also adds relevance for life-sciences and advanced-manufacturing companies where an IPO delay may result from regulatory or technical milestones rather than poor management. A redemption clause that triggers automatically on a fixed date can create a severe liquidity problem for a company that remains fundamentally valuable. Investors and founders may be better served by a staged remedy or negotiated extension if the legal documents permit it.
Redemption rights are especially important for technology funds because portfolio-company exits are uncertain. A semiconductor or biopharma company may miss an IPO deadline for reasons unrelated to fraud or business failure, including market conditions, regulatory review or delayed product milestones. Investors should therefore decide whether the redemption right is intended as a true cash exit, a negotiating mechanism or protection against specific founder conduct. The drafting should match that economic purpose.
Xu’s fund and investment experience is relevant because the obligation can be placed on different parties. A founder or controlling shareholder may promise to repurchase the investor’s shares, while the target company may also undertake a redemption or compensation obligation. Chinese judicial guidance distinguishes between validity of the agreement and whether performance by the target company is legally permissible under mandatory company-law rules. That distinction should be understood before the investor assumes that a written clause guarantees cash repayment.
Her M&A and capital-markets background also matters once a redemption dispute begins. An investor may prefer a secondary sale, strategic acquisition or negotiated extension over immediate enforcement if the company remains valuable. Counsel should compare those routes and preserve leverage without forcing the target into an unnecessary liquidity crisis that reduces everyone’s recovery.
For fund managers, redemption drafting also has portfolio-level implications. If several investors hold different redemption dates, priorities or security packages, enforcing one investor’s rights can change the negotiating position of the entire cap table. Counsel should therefore review side letters and historical financing rounds together rather than interpret the latest investment agreement in isolation.
Xu’s profile is particularly useful where investors need to move between transaction drafting and exit enforcement. Redemption rights, valuation-adjustment arrangements and security packages are negotiated at investment, but their real value is tested only years later when an IPO or sale does not happen as planned. Her funds, M&A and capital-markets background is relevant to that full investment lifecycle.
Capability
